Three popular GLP-1 receptor agonists carried similar risks for serious gastrointestinal (GI) events among adults with type 2 ...

Among over 151,000 patients, use of GLP-1 drugs was linked to a lower risk of death compared with no use (adjusted HR 0.77, ...

A comprehensive review in The Journal of Clinical Investigation finds no overall link between GLP-1 receptor agonists and ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Despite ...

Although findings from a large retrospective study supports these positive effects of taking a GLP-1, it’s unclear whether ...

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded ...

An Institute for Clinical and Economic Review report concluded that the GLP-1 drugs tirzepatide and semaglutide (Ozempic, ...

In a large real-world Italian cohort, GLP-1 receptor agonist therapy led to measurable rates of type 2 diabetes remission, ...

New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...

Patients with psoriatic arthritis who received GLP-1 receptor agonists exhibited lower risks for mortality and cardiovascular ...

A recent retrospective study published in the Frontiers in Endocrinology suggests that glucagon-like peptide-1 receptor ...